Quick Answer
BioRestorative Therapies, Inc. reported Gross Profit of $335.9 thousand for the year ending 2025.
- BioRestorative Therapies, Inc. showed a decrease of -9.9% in Gross Profit from 2024 to 2025.
- This data is from BioRestorative Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $0.00 | Q1 2012: $0.00 | Q2 2012: $10.0 thousand | Q3 2012: $4.0 thousand | Q1 2013: $968.00 | Q2 2013: $389.00 | Q3 2013: $115.00 | Q1 2014: $315.00 | Q2 2014: $133.6 thousand | Q3 2014: $93.8 thousand | Q1 2015: $108.5 thousand | Q2 2015: $74.1 thousand | Q3 2015: $45.2 thousand | Q1 2016: $9.1 thousand | Q2 2016: $16.1 thousand | Q3 2016: $5.0 thousand | Q1 2017: $7.0 thousand | Q2 2017: $20.0 thousand | Q3 2017: $16.0 thousand | Q2 2023: $64.5 thousand | Q3 2023: $30.7 thousand | Q1 2024: $35.0 thousand | Q2 2024: $82.6 thousand | Q3 2024: $215.4 thousand | Q1 2025: $22.1 thousand | Q2 2025: $294.6 thousand | Q3 2025: $1.2 thousand.
- Historical annual values: Fiscal year 2025: $335.9 thousand | Fiscal year 2024: $372.9 thousand | Fiscal year 2023: $145.8 thousand | Fiscal year 2017: $81.0 thousand | Fiscal year 2016: $36.3 thousand | Fiscal year 2015: $367.4 thousand | Fiscal year 2014: $202.2 thousand | Fiscal year 2013: $1.5 thousand | Fiscal year 2012: $14.3 thousand | Fiscal year 2011: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: